Oxford University spinout Vaccitech raised £ 20 million ( $ 27 m ) through Series A funding from GV and Sequoia China , along with existing investor Oxford Sciences Limited and Neptune Ventures . The funds will enable Vaccitech to expand its business , develop its lab structure and push its products , including a universal influenza vaccine and a breast cancer therapeutic in development . An Oxford University Innovation spokesman adds that it’s not seeing a major shift change in tech-focused VCs backing life sciences, although he notes: “We are beginning to see more corporate VCs come in earlier.” Vaccitech CEO , Tom Evans , said that the company is much faster at bringing its products to the market than most , because it is in Phase II of clinical trials for the flu and prostate cancer vaccines .
Oxford University spinout Vaccitech raised £ 20 million ( $ 27 m ) through Series A funding from GV and Sequoia China , along with existing investor Oxford Sciences Limited and Neptune Ventures . The funds will enable Vaccitech to expand its business , develop its lab structure and push its products , including a universal influenza vaccine and a breast cancer therapeutic in development . Vaccitech CEO , Tom Evans , said that the company is much faster at bringing its products to the market than most , because it is in Phase II of clinical trials for the flu and prostate cancer vaccines .